PK in Healthy Volunteers
4
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Cbd Softgel Capsules 600 Mg
Research Leaders
6 sponsors active, led by Drugs for Neglected Diseases
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Ultra-Micronized vs Liposomal PEA 600 mg: A Crossover PK Study in Healthy Subjects
Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers
A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers
Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions
Research Network
Common Treatments
- Cbd Softgel Capsules 600 Mg1
- Fexinidazole1
- Epidyolex1
- Ultramicronised Pea1
- Pegmethugcsf1
Active Sponsors
- Drugs for Neglected Diseases1
- NW PharmaTech Ltd1
- Novotech CRO1
- Sanofi1
- S&R Farmaceutici S.p.A.1
Top Investigators
Drugs for Neglected Diseases initiative
SGS Aster
Related Conditions
- Liposomal Encapsulation1
- Palmitoylethanolamide1